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Abstract
Background: Radio-frequency ablation (RFA) has been employed in the treatment of Barcelona Clinic Liver Cancer (BCLC)
early stage hepatocellular carcinoma (HCC) as curative treatments.
Aim: To assess the effectiveness and the safety of RFA in patients with early HCC and compensated cirrhosis.
Methods: A cohort of 151 consecutive patients with early stage HCC (122 Child-Pugh class A and 29 class B patients) treated
with RFA were enrolled. Clinical, laboratory and radiological follow-up data were collected from the time of first RFA. A
single lesion was observed in 113/151 (74.8%), two lesions in 32/151 (21.2%), and three lesions in 6/151 (4%) of patients.
Results: The overall survival rates were 94%, 80%, 64%, 49%, and 41% at 12, 24, 36, 48 and 60 months, respectively.
Complete response (CR) at 1 month (p,0.0001) and serum albumin levels (p = 0.0004) were the only variables
indipendently linked to survival by multivariate Cox model. By multivariate analysis, tumor size (p = 0.01) is the only variable
associated with an increased likehood of CR. The proportion of major complications after treatment was 4%.
Conclusions: RFA is safe and effective for managing HCC with cirrhosis, especially for patients with HCC #3 cm and higher
baseline albumin levels. Complete response after RFA significantly increases survival.
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Introduction
The extensive application of surveillance programs for early
detection of hepatocellular carcinoma (HCC) has increased the
number of tumors detected within the Milan criteria [1] and
potentially responsive to curative treatments, such as liver
transplantation, resection and percutaneous or surgical ablation.
[2,3] Radiofrequency ablation (RFA) is currently recognized as an
effective local treatment [2] in patients with Barcelona Clinic Liver
Cancer (BCLC) early stage hepatocellular carcinoma (HCC) not
elegible to surgical treatments. However, the 5-year survival rate of
patients with HCC 5 cm after RFA is lower 50% because of the
high risk of recurrence [4] and the influence of the severity of the
underlying liver disease.
The aims of this prospective cohort study of BCLC early stage
HCC patients treated with RFA as first-line treatment were:
1. to assess the effectiveness of RFA in HCC patients;
2. to select the optimal candidate for RFA by identification of
predictors of overall survival.
Materials and Methods
Patients
From January 2000 to May 2011, 825 consecutive patients with
cirrhosis and a new diagnosis of HCC were observed at our Liver
Unit.
Cirrhosis was diagnosed by histological or clinical features and
the liver function was evaluated according to Child-Pugh score.
The diagnosis of HCC was performed by ultrasound guided
biopsy or by multiphasic contrast-enhanced computed tomogra-
phy or gadolinium-enhanced magnetic resonance.
All patients were evaluated according to European Association
for the Study of the Liver criteria [5] up to 2005, and to American
Association for the Study of Liver Diseases criteria [6] from
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January 2006. HCC staging and the choice of treatment were
performed according to the BCLC algorithm. [7].
Extra-hepatic disease was assessed with multidetector multi-
phasic CT and chest radiography. Bone metastases were sought by
scintigraphy if clinically suspected.
In the study period 151 were treated by RFA as first-line
treatment. In all cases a multidisciplinary panel including a liver
surgeon, an interventional radiologist, and hepatologists reviewed
the patients’ files and imaging examinations. Inclusion criteria
were: (a) tumor detectable by ultrasound (US) with an acceptable
and safe path between the lesion and skin as shown on US, (b)
patients who refused surgery or orthotopic liver trasplantation or
with associated diseases contraindicating surgery; (c) a single HCC
of 5 cm in diameter or smaller or as many as three HCCs each
3 cm in diameter or smaller; (d) cirrhosis classified as Child-Pugh
class A or B; (e) absence of portal vein thrombosis or extrahepatic
metastases; (f) platelet count .40,000/ mm3; prothrombin time
ratio .40%. Exclusion criteria were tumors .5 cm, extrahepatic
metastases, portal vein thrombosis, ascites, dilated bile ducts or
cardiac arrhythmia. We used a commercial ultrasound (US)
scanner (ESAOTE biomedica AU5) with a guide device. Before
starting the procedure, all the patients were staged with spiral
computed tomography (CT) scan, alfa-fetoprotein (AFP), and
chest X-ray. The mean time elapsed between HCC diagnosis and
the RFA procedures was 1 month.
The study was approved by the local ethics committee of the
‘‘Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone’’
and a written informed consent was obtained from all patients.
RF Ablation Procedures
RFA was performed under US guidance with a 150W generator
(Model 1500 L; RITA Medical System, Mountain View, Calif.),
connected to an expandable 15–14-gauge electrode with a 2.0-cm-
long exposed tip (expandable by means of seven hooks). After
administration of analgesia (50 to 60 mg of propofol and 0.05 to
0.1 mg of fentanyl) as well as local anesthesia (5 to 15 mL of 1%
lidocaine) by an anesthesiologist, a RFA needle was first inserted
into the tumor. The electrode was placed into the centre of the
lesion maintaining the temperature of the needle tip at 100uC or
more for 10–12 min. After ablation, the needle was retracted
maintaining its tip hot in order to prevent by thermal coagulation
seeding or haemorrhage along the electrode track. For patients
with multiple tumors, all lesions were treated in one single session.
Outcomes and Follow-up
The primary outcome was overall survival. Follow-up time was
defined as the number of months from first RFA to orthotopic liver
transplantation (OLT), last contact with the patient, or death.
Response rate magnitude was defined according to the
European Association for the Study of the Liver (EASL) criteria.
[5] These are addressed by recent guidelines. [3,8] EASL response
criteria are defined as follows:
N complete response (CR), defined as absence of any enhancing
tissue;
N partial response (PR), defined as .50% decrease in enhancing
tissue;
N and stable disease, defined as ,50% decrease in enhancing
tissue.
Progressive disease is defined by at least a 25% increase in
enhancing tissue of the treated tumor. Treatment failure was
defined as the presence of viable tumor at the end of therapy.
The follow-up protocol included clinical assessment by physical
examination, ultrasound scan and biochemistry every 3 months,
and by multiphasic CT scan every 6 months. In our study, RFA-
related morbidity was defined as any complication within 2 weeks
of each session of RFA. RFA-related mortality was defined as
death from a complication within 2 weeks of each session of RFA.
Figure 1. Probability of Overall Survival in 151 Patients with HCC in compensated Cirrhosis Treated with RFA.
doi:10.1371/journal.pone.0070016.g001
RFA for HCC
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Statistical Evaluation
Data were collected by experienced medical personnel involved
in the study using a common electronic database. The primary
outcome weas assessed by intention-to-treat, while continuous
variables were expressed as mean standard deviation. Categorical
variables were analyzed as frequency and percentages. The
Kaplan-Meier model was used to estimate survival. Differences
in the survival rate were assessed by log-rank testing. Potential
prognostic variables were evaluated as predictors of survival by
Cox models. All variables at baseline included in Table 1, with the
addition of treatment response, and number of treatments, during
follow-up, were studied at univariate analyses. Variables with a p
value of ,0.10 at univariate analysis were included in the final
multivariate model. To avoid the effect of co-linearity with
albumin, bilirubin and International Normalised Ratio, Child-
Pugh score was not included in the same multivariate model.
Multiple logistic regression model was used to assess the
relationship of complete radiological response with the demo-
graphic, laboratory, clinical, and tumor staging characteristics of
patients. For all analyses, P#0.05 was considered statistically
significant. All p values were two-tailed, and all confidence
intervals (CIs) were 95%. All multivariate analyses were done with
PROC PHREG in SAS version 8.1 (SAS Institute, Inc, Cary, NC,
USA).
Results
Patient Features at Baseline
The study population consisted of 151 patients with HCC
secondary to cirrhosis of different etiologies treated by RFA. The
demographic, clinical and tumor staging features of the 151
patients are given in Table 1. Chronic HCV infection was the
Table 1. Demographic, Laboratory, Clinical and Tumor Staging Characteristics of 151 Patients with HCC in Compensated Cirrhosis
Treated with RFA.
Characteristic Child-Pugh A (n=122) Child-Pugh B (n=29)
Age – years 6767.5 6765.4
Male – no. (%) 82 (67) 20 (69)
Etiology of Cirrhosis-no. (%)
Anti-HCV positivity 108 (88.4) 25 (86.4)
HBsAg positivity 10 (8.2) 1 (3.4)
Alcohol abuse 3 (2.6) 1 (3.4)
NAFLD 1 (0.8) 2 (6.8)
Hepatic Encephalopathy-no. (%)
None 122 (100) 29 (100)
Ascites – no. (%)
None 122 (100) 29 (100)
Albumin – g/dl 3.760.5 3.260.4
International Normalised Ratio 1.1060.12 1.261.5
Total Bilirubin – mg/dl 1.260.9 2.160.5
Platelet6103/ mmc 105658 72632
Creatinine-mg/dl 0.860.3 0.960.3
MELD Score 9.061.9 9.062.1
Oesophageal varices – no. (%)
None 53 (43.5) 5 (17.2)
F1 48 (39.3) 16 (55.2)
F2/F3 21 (17.2) 8 (27.6)
Portal Vein Thrombosis – no. (%)
None 122 (100) 29 (100)
AFP - ng/mL 756115 1326633
Number of Nodules (%)
1 90 (73.3) 23 (79.3)
2 27 (22) 5 (17.2)
3 5 (4.7) 1 (3.5)
Tumor size– no. (%)
3 cm 103 (84.4) 25 (86.2)
.3 cm 19 (15.6) 4 (13.8)
Note. Values are mean 6 SD.
Abbreviations: IU, international units; AFP, alpha fetoprotein; HCV, hepatitis C virus; HBV, hepatitis B virus; NAFLD, Nonalcoholic fatty liver disease; MELD, Model for End-
Stage Liver Disease.
doi:10.1371/journal.pone.0070016.t001
RFA for HCC
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dominant etiology, followed by chronic hepatitis B virus (HBV)
infection.
At presentation 122 of the 151 patients (81%) were in the Child-
Pugh A class. None of the 29 Child-Pugh B patients had ascites,
jaundice, or hepatic encephalopathy.
Figure 2. Probability of Overall Survival in 151 Patients with HCC in compensated Cirrhosis Treated with RFA, according to Child-
Pugh classes.
doi:10.1371/journal.pone.0070016.g002
Figure 3. Probability of Overall Survival in 122 Child-Pugh A Patients with HCC Treated with RFA, according to radiological
response (Complete response [solid line] vs treatment failure [dashed line]).
doi:10.1371/journal.pone.0070016.g003
RFA for HCC
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A single lesion was observed in 74.8%, and two or three lesions
in 25.2% of patients.
The tumor size was #3 cm 128/151 (84.8%) of the patients.
Follow-up
The mean length of follow-up after RFA was
35.6626.7 months (median 29.6 months, range 4–139 months).
Six (4%) patients, lost during follow-up, were censored at the last
visit. During follow-up, 71 patients died, while 80 (53%) were alive
at the end of the study (Table 2).
CR after RFA was achieved in 118 patients (78%), in 109 after
one session, in 9 after two sessions (no significant differences in
term of tumor staging characteristics were found in this subgroup
of patients). Treatment failure was observed in 33/151 patients
(22%), including 10 patients with 3 HCC nodules, 15 patients with
HCC nodules larger than 4 cm and 8 patients with HCC nodules
located in areas difficult to reach. During follow-up, 80 of 118
patients who achieved CR developed recurrences (local recur-
rences in 46 patients, while distant recurrences in 34 patients).
Median time to recurrences was 17 months (range 13–21).
Median overall survival after RFA was 47.6 months (95%
confidence interval [CI] 41–61.1) for the entire group. Median
survival was longer in patients who achieved CR after RFA
(59.4 mo, 95%CI 50.8–68.0) than among patients who failed
treatment (26 mo, 95%CI 19.4–32.5). The overall survival rates
(Figure 1) were 94%, 80%, 64%, 49%, and 41% at 12, 24, 36, 48
and 60 months, respectively.
Survival was longer among Child-Pugh A class patients (96, 86,
73, 59 and 49% at 12, 24, 36, 48 and 60 months, respectively)
than among Child-Pugh B class patients (84, 51, 23, 0.1, and 0%
at 12, 24, 36, 48 and 60 months, respectively) (P,0.001 by log-
rank test) (Figure 2). Figure 3 and figure 4 show probability of
overall survival according to radiological response (Complete
response vs treatment failure) in 122 Child-Pugh A Patients and in
29 Child-Pugh B Patients with HCC treated with RFA,
respectively.
Treatment Safety
No patient death was treatment-related. The proportion of
major complications after treatment was 4% (Table 2). One
patient developed portal vein thrombosis soon after treatment.
Other major reported complications were subcapsular hematoma
(1 case), intrahepatic abscess (1 case), pleural effusion (1 case), and
neoplastic seeding of the needle track (1 cases). The three most
frequent minor complications after treatment were pain requiring
major analgesia, transient episode of fever and skin burns.
Analysis of Factors Affecting the Survival of Patients and
Complete Response
Cox regression analysis by Cox model showed that complete
response after 1 month (HR 0.3; 95% CI: 0.18–0.53; P,0.0001);
and albumin levels (HR 0.4; 95% CI: 0.2–0.64; P = 0.0004) were
independent and significant predictors of overall survival (Table 3).
By multivariate analysis, tumor size (#3 cm vs .3 cm) is the
only variable associated with an increased likehood of CR (Odds
ratio = 2.8; 95% CI: 1.2–6.6; P = 0.01).
Discussion
HCC secondary to cirrhosis is a complex and heterogeneous
disease with wide variations during its clinical course. [9,10]
Surveillance and recal strategy for HCC is now an established
practice [2,11,12,13] since early detection of malignant liver
nodules is critical to select patients with limited disease, that are
potential candidates for curative treatments. Radical treatments
(surgical resection, liver transplantation and percutaneous abla-
Figure 4. Probability of Overall Survival in 29 Child-Pugh B Patients with HCC Treated with RFA, according to radiological response
(Complete response [solid line] vs treatment failure [dashed line]).
doi:10.1371/journal.pone.0070016.g004
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tion) are usually offered in referral Centres to 30–40% of patients
with early-stage HCC, [3] with reported 5-year survival rates of
40–70% for treated patients vs. less than 20% in those left
untreated. [3,9].
In the present prospective study we observed, in a large
prospective cohort, that RFA is a safe and effective procedure for
the treatment of early stage HCC patients.
The overall survival rate was 41% at 60 months and overall
median survival was 47.6 months; complete response was obteined
in 78% of patients and we observed a recurrence rate of 66.8%.
Our data are consistent with those already published and confirm
the importance of RFA in the treatment of patients with HCC at
early stage. [4,14,15].
Our analysis, specifically designed to identify prognostic factors
of survival, shows that, as previously reported, [16,17,18] overall
survival depends strictly on complete radiological response. This
relevant result was already found about ten years ago, by Sala
et al. that showed that initial complete response to percutaneous
ablation was associated with an improved survival in both Child-
Turcotte-Pugh class A and B patients with nonsurgical HCC. In
this line, the present paper is a confirmatory contribution on a
peculiar aspect that is still valid ten years later its first reporting.
[16] So, complete response is a relevant surrogate end-point that
should be planned and carefully assessed by multiphasic CT or
MR scan in all patients who undergo RFA. [8,19].
Among the three laboratory parameters of the Child-Pugh score
(i.e., albumin, bilirubin, and INR), only the albumin level was
found to be significant at multivariate analysis, suggesting that, in
addition to cancer-related feature (tumor size), liver function of the
underlying cirrhosis must be carefully evaluated before selecting
patients for RFA.
This is not novel, but is not a trivial point, because it is well
known that cirrhosis underlies HCC in most of the patients and
the functional impairment of the underlying liver has a significant
impact on prognosis, irrespective of the tumour stage and the
effect of tumor therapy.
We also found a correlation of tumor size with an increased
likelihood of complete response; this information might help with
pretreatment patient stratification in the design of therapeutic
trials and in clinical practice therapeutic decisions.
The Current Study was Affected by Certain Limitations
Lack of histologic data, in supporting radiologic assessment of
complete response, suggests that local recurrence could be
interpreted as failure to provide adequate local control of HCC,
particularly when viable tumor was detected within 6 months from
treatment in spite of a radiologic assessment of complete response
one month after treatment.
Another weakness of our prognostic model is the lack of data on
molecular factors, such as gene expression profiling, which can
have some impact on patient’s outcome. [20,21] However, The
predictive ability of our model, including simple and easy clinical
and radiological predictors was excellent, underscoring the
applicability of our results to new populations and settings,
particularly in real clinical practice, where complex and expensive
tests are not available.
What are the Implications of These Results for Current
Practice?
In accordance with current guidelines, [2,3] we confirmed that
RFA is a safe and efficacy curative option for the treatment of
early stage HCC patients. This is particular relevant whereas the
number of patients who undergo liver transplantation is minimal,
compared with the total number of patients with HCC, because of
the shortage in donors and the stringent transplantation criteria for
this indication. [22,23] Moreover, it is important to remember that
the waiting list for OLT is often long and that OLT is not usually
indicated in patients .65 years. Therefore, in these two groups of
patients, RFA is indicated.
Recently, RCT showed no significant differences in survival
rates (overall or disease-free) after RFA or resection; [24] however,
because most patients will experience several episodes of
recurrence, comparison between resection and RFA is very
difficult, especially in terms of their repeatability. In this line,
even if different guidelines for the management of HCC provide
indications for the use of various treatments as monotherapies,
Table 2. Follow-up of 151 Patients with HCC in Compensated
Cirrhosis Treated with RFA.
Characteristics Value
Complete response-no. (%) 118 (78)
after one cycle 109 (92)
after two cycles 9 (8)
Recurrence after compete response-no. (%) 80 (67.8)
local recurrence 46 (39)
distant recurrence 34 (28.8)
Complications after RFA – no. (%) 5 (4)
portal vein thrombosis 1 (0.8)
subcapsular hematoma 1 (0.8)
intrahepatic abscess 1 (0.8)
pleural effusion 1 (0.8)
seeding 1 (1.8)
Other Treatments – no. (%) 87 (57.6)
RFA 41 (27.1)
TACE 26 (17.2)
OLT 2 (1.3)
RFA+TACE 7 (4.6)
Sorafenib 11 (7.3)
Extra-hepatic spread – no. (%) 11 (7.3)
Overall Survival, Median -mo (95% CI) 47.6 (41–61)
Child-Pugh A (n = 122) 59.4 (48–72)
Child-Pugh B (n = 29) 26 (15–41)
Recurrence-Free Survival, Median -mo (95% CI) 17 (13–21)
Death -no. (%) 71 (47)
Abbreviations: TACE, Transarterial chemoembolization; OLT, orthotopic liver
transplantation; PEI, percutaneous ethanol injection; RFA, radiofrequency
thermal ablation; CI, confidence interval.
doi:10.1371/journal.pone.0070016.t002
Table 3. Predictor of Survival in 151 Patients with HCC in
Compensated Cirrhosis Treated with RFA.
Variables (code) Hazard Ratio CI 95% P value
Complete response after
RFA (yes vs no)
0.3 0.18–0.53 ,0.0001
Albumin-g/dl (continue) 0.4 0.2–0.64 0.0004
Abbreviations: HR, hazard Ratio; CI, confidence interval; RFA, radio-frequency
ablation.
doi:10.1371/journal.pone.0070016.t003
RFA for HCC
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none of these give infication for a multimodal approach (often used
in clinical practice) that combines various techniques used, either
as first-line therapy or as a rescue (second-line) approach after the
failure of a monotherapy. [25,26] Despite promising results with
RFA in monotherapy, the incidence of local and distant
recurrence remain challenging. Role of combined locoregional
treatment (RFA plus transarterial chemoembolization), especially
for nodules .3 cm, should be assessed. [27].
Moreover, given high rate of recurrences after complete
response, numerous studies of postoperative adjuvants (tertiary
prevention) after resection or ablative therapies have been
performed, but the results are not definitive. In this line, an
ongoing phase III clinical trial is testing adjuvant sorafenib for
prevention of recurrence (STORM trial).
In this study, no procedure-related death was observed and
additional major complications occurred (portal vein thrombosis,
pleural effusions, intrahepatic abscess, subcapsular hematoma and
seeding) in 4% of patients. Complication rate was similar to those
usually reported.
In conclusion, the main results of our study are : 1) a complete
response after RFA and high baseline albumin level significantly
increase survival; 2) the overall survival rate at 60 months is 41%,
and remains low because of the high rate of recurrence (67.8%); 3)
a tumor size .3 cm significantly affects the response after RFA; 4)
RFA appears as a safe and effective treatment for early stage HCC
patients.
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